All In Biotech

Drug Trial Radar · NCT00457457

Study the Effects of Different Doses of UK-369,003 in Men With Lower Urinary Tract Symptoms.

A Multi-center, Randomized, Parallel Group, Double-blind, Placebo Controlled Proof of Concept and Dose Ranging Study With an Active Control to Assess the Efficacy and Safety/Tolerability of UK-369,003 Immediate Release (IR) and Modified Release (MR) in the Treatment of Men With Lower Urinary Tract Symptoms (LUTS) With and Without Erectile Dysfunction (ED)

Last checked: Nov 19, 2026Latest source record: Dec 19, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 609 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

609

Actual

Start

May 2007

Primary completion

Apr 2008

Study completion Apr 2008

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Apr 6, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
Male only, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a 12 week study in which different doses and formulations of UK-369,003 will be administered to patients with a diagnosis of enlarged prostate. Patients will complete a series of questionnaires before, during and after treatment to assess if UK-369,003 has improved their urinary symptoms and erectile function . There will be several blood samples taken during the study to asses the level of drug in the blood and correlate it with the responses to the questionnaires.

Conditions

  • Prostatic Hyperplasia

Interventions

  • TamsulosinDrug

    Tamsulosin hydrochloride capsules, 0.4 mg. Tamsulosin hydrochloride is an antagonist of alpha1A adrenoceptors in the prostate

  • UK-369,003Drug

    UK 369,003 is a highly selective and potent inhibitor of PDE5. It has increased selectivity for PDE5 over PDE6 (\>80 fold) compared to sildenafil (\~10 fold). Two recently completed trials have shown efficacy for UK-369,003 in treating subjects with ED

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in international prostate symptom scoreTime frame: 12 weeks

Locations

46 sites in 15 countries. Site status is shown where the registry gives one.

  • Pfizer Investigational Site

    Herston, Queensland, Australia

  • Pfizer Investigational Site

    Adelaide, South Australia, Australia

  • Pfizer Investigational Site

    Brussels, Belgium

  • Pfizer Investigational Site

    Brussels, Belgium

  • Pfizer Investigational Site

    Edegem, Belgium

  • Pfizer Investigational Site

    Calgary, Alberta, Canada

  • Pfizer Investigational Site

    London, Ontario, Canada

  • Pfizer Investigational Site

    Pointe-Claire, Quebec, Canada

  • Pfizer Investigational Site

    Santiago, Chile

  • Pfizer Investigational Site

    Temuco, Araucania, Chile

  • Pfizer Investigational Site

    Medellín, Antioquia, Colombia

  • Pfizer Investigational Site

    Barranquilla, Atlántico, Colombia

  • Pfizer Investigational Site

    Bogota, Cundinamarca, Colombia

  • Pfizer Investigational Site

    Bogota, Cundinamarca, Colombia

  • Pfizer Investigational Site

    Cali, Valle del Cauca Department, Colombia

  • Pfizer Investigational Site

    Aalborg, Denmark

  • Pfizer Investigational Site

    Aarhus N, Denmark

  • Pfizer Investigational Site

    Gentofte Municipality, Denmark

  • Pfizer Investigational Site

    Helsinki, Finland

  • Pfizer Investigational Site

    Kuopio, Finland

  • Pfizer Investigational Site

    Oulu, Finland

  • Pfizer Investigational Site

    Tampere, Finland

  • Pfizer Investigational Site

    Larissa, Greece

  • Pfizer Investigational Site

    Rio, Greece

  • Pfizer Investigational Site

    Thessaloniki, Greece

  • Pfizer Investigational Site

    Foggia, Italy

  • Pfizer Investigational Site

    Siena, Italy

  • Pfizer Investigational Site

    Riga, Latvia

  • Pfizer Investigational Site

    Kaunas, Lithuania

  • Pfizer Investigational Site

    Kaunas, Lithuania

  • Pfizer Investigational Site

    Vilnius, Lithuania

  • Pfizer Investigational Site

    Bydgoszcz, Poland

  • Pfizer Investigational Site

    Bydgoszcz, Poland

  • Pfizer Investigational Site

    Gdansk, Poland

  • Pfizer Investigational Site

    Gdynia, Poland

  • Pfizer Investigational Site

    Mysłowice, Poland

  • Pfizer Investigational Site

    Wejherowo, Poland

  • Pfizer Investigational Site

    Bratislava, Slovakia

  • Pfizer Investigational Site

    Malacky, Slovakia

  • Pfizer Investigational Site

    Nitra, Slovakia

Showing 40 of 46 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.